John A. McLean, Ph.D.
Stevenson Prof. of Chemistry, Department of Chemistry
High-Dimensional Molecular Phenomics in Systems, Synthetic, and Chemical Biology
Advanced technologies allow us to measure the molecules in a biological system in a matter of seconds. Using tools developed in other fields such as the finance sector, astronomy, and physics have opened many opportunities when applied to biological big data. From the development of humanlike miniature organs in synthetic biology, to new drug reservoirs in extremophile organisms like bacteria, we highlight new directions for understanding and harnessing biology in medicine and drug discovery.
One of the predominant challenges for phenotypic measurements is the broad-scale characterization of the molecular inventory in cells, tissues, and biological fluids. Advances in computational systems biology rely heavily on the experimental capacity to make integrated omics measurements, i.e. integrated metabolomics, proteomics, lipidomics, glycomics, etc., accompanied with minimal sample preparation, fast measurements, high concentration dynamic range, low limits of detection, and high selectivity. This confluence of figures-of-merit place demanding challenges on analytical platforms for such analyses. Recent innovative advances in integrated omics measurement strategies in the context of systems, synthetic, and chemical biology are described. New approaches in bioinformatics and biostatistics are presented to approach biological queries from an unbiased and untargeted perspective, as well as to quickly mine the data gathered to provide targeted and actionable information.
Christiane Auray-Blais, LL.M., Ph.D.
Director, Quebec Provincial Mass Urinary Screening Program for Hereditary Metabolic Disorders
Université de Sherbrooke
The Significance of Mass Spectrometry for Translational Research in Precision Medicine
Translational research projects performed in my laboratories have been the focus of mass spectrometry approaches for biomarker discovery, early detection, confirmation of diagnosis, as well as monitoring and follow-up of patients. From preventive genetic medicine in the newborns to better understand the pathophysiology of neurodegenerative diseases, we have worked with patients at various ages, and a wide spectrum of complex genetic diseases. With the advancement of more refined mass spectrometry strategies for biomarker analysis, it is now possible to aim at precision medicine and try to overcome the challenges related to the marked phenotypic/genotypic variability found in many rare diseases.
Afternoon Parallel Sessions
AMST – Innovation in Mass Spectrometry
The session will focus on the latest innovations and technology developments in research-based mass spectrometry, including both direct-ionization imaging mass spectrometry, and high-performance ion mobility.
This session will focus on how MS imaging, discovery omics, and targeted workflows are opening up new horizons on characterizing and unravelling both normal and diseased biology.
Gain insights into how recent innovations and solutions are enabling biopharmaceutical organizations to strengthen their in-house LC-MS analysis capabilities to achieve more streamlined workflows, and faster decision making and greater productivity across the biopharmaceutical discovery, development, and manufacturing pipeline.
Chemical & Materials:
Gain insights from scientists who use mass spectrometric techniques including high-resolution mass spectrometry (HRMS), ion mobility, and progressive informatics to advance fine chemicals and materials science. Application areas to be discussed include energy, polymeric materials, packaging materials, and more.
Food & Environmental:
In this session, hear how high-resolution MS is practically applied to beer and pork analysis. For those focused on a healthier lifestyle, we’ll discuss research using routine ion mobility for profiling / characterizing food using metabolomics.
This session will highlight LC-MS technologies, platforms and strategies being implemented in notable academic, pharmaceutical, and contract research labs, and demonstrate the utility of tandem quadrupole, high- resolution, and ion mobility mass spectrometry for a range of activities including high-throughput ADME peptide screening, high confidence metabolite identification, protein biotransformation monitoring, and peptide therapeutic quantification in translational research. Implications for pre-clinical and clinical studies will be presented.